OT C001
Alternative Names: NK-001 - EMERCell; OT-C001Latest Information Update: 28 Jul 2025
At a glance
- Originator EMERCell
- Developer EMERCell; Onward Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diffuse large B cell lymphoma
- No development reported Acute myeloid leukaemia; Lymphoma
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia(Combination therapy) in France (Parenteral)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia(Combination therapy) in Switzerland (Parenteral)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Lymphoma(Combination therapy) in Switzerland (Parenteral)